We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Neose Technologies, Inc. (Nasdaq: NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE: NVO) under the license agreements entered into in November 2003 to use Neose's GlycoPEGylation(TM) technology to develop next-generation versions of three currently-marketed therapeutic proteins.
US-based public interest group Defenders of Property Rights (DPR) is confident that Brazil's government will back away from threats to seize patents on a number of HIV/AIDS drugs developed by US companies.
The Czech government is continuing its drive to cut healthcare expenditure by setting new spending limits on expensive drugs for hospitals in the public sector.
Indian drug sales are forecast to reach INR600bn (US$13.09bn) in the 2007-2008 financial year, an increase of 11% on current levels, while exports should grow 18%, according to a new report released by the Associated Chambers of Commerce and Industry of India.
Valera Pharmaceuticals announced today that its subsidiary company, Valera Pharmaceuticals Ireland Limited, received marketing authorization from the Danish Medicines Agency for VANTAS(TM), its 12-month implant for the palliative treatment of advanced prostate cancer.
SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceutical product candidates and non-pharmaceutical products, today announced the completion of $2,500,000 in new long-term secured debt financing from Oxford Finance Corporation of Virginia.
THE carve up of Mayne Group's underperforming operations was formalised yesterday, after two spin-offs -- Symbion Health and Mayne Pharma -- debuted on the Australian Stock Exchange.
Generics maker Teva Pharmaceuticals Industries Ltd is considering buying 3i Group PLC's German generics company Betapharm, Die Welt's Saturday edition reported, citing sources.